Navigation Links
XOLAIR Safety Study Continues to 2012 Despite Increased Rate of Occurrence of Heart Problems, Onder Law Firm Offers Free XOLAIR Case Review
Date:11/14/2009

The FDA is reviewing preliminary safety information on XOLAIR allergic asthma medication. Problems with XOLAIR have been linked to heart attack and stroke. The Onder Law Firm is offering a free case review to those or families of those who may have experienced serious health problems after taking XOLAIR.

St. Louis, MO (Vocus) November 14, 2009 -- The FDA is evaluating interim safety findings from Genentech, Inc. in an ongoing study of XOLAIR problems. XOLAIR (omalizumab) is an injected drug for asthma related allergies. The interim results of this study, which is being conducted by the drug’s manufacturer, suggests an increased number of cardiovascular (heart attack) and cerebrovascular (stroke) adverse events in a group of patients using Xolair compared to a group of patients not given the drug (control group).

The possible association has been identified based on interim results from an ongoing study of Xolair known as Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS). The results this study are not expected until 2012. Although the FDA and the drug manufacturer have not recalled XOLAIR, the FDA wants consumers to be aware of increased risks from taking XOLAIR, specifically heart attack/heart disease and stroke.

The FDA originally approved XOLAIR in 2003 but announced in February of 2007 that it was requesting a stronger warning for XOLAIR because it may cause anaphylaxis, a reaction that may include trouble breathing, chest tightness, dizziness, fainting, itching and hives, and swelling of the mouth and throat.

“It is important for persons who have used or are using XOLAIR to be aware of the side effects and hazards,” stated James Onder of Onder, Shelton, O’Leary & Peterson, LLC. The firm’s XOLAIR safety information web site contains information regarding XOLAIR side effects and the rights those suffering from them may have. The attorneys of The Onder Law Firm will review will provide free case review to persons having experienced side effects or medical problems after taking XOLAIR. The Onder Law Firm provides experienced legal representation without fee unless it collects for its clients.

About The Law Firm
Onder, Shelton, O’Leary & Peterson, LLC is a personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O’Leary & Peterson has represented clients throughout the United States in pharmaceutical litigation such as Vioxx, Digitek, Ethex and others, and other law firms throughout the nation often seek its experience and expertise on complex litigation. For more information, visit www.onderlaw.com or call 1-877-ONDER-LAW.

# # #

Read the full story at http://www.prweb.com/releases/xolair/safety/prweb3207784.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. FDA Investigating Safety of Asthma Drug Xolair
2. FDA Questions Safety of Caffeinated Alcoholic Drinks
3. Centerplate and the Capital Improvement Board Investigating Food Safety Violations at Lucas Oil Stadium to Ensure Highest Standards Achieved and Operational Excellence
4. New Polls, Reports Highlight The Need To Update The U.S. Food Safety System And To Make Our Food Safe For The Holidays
5. New Research Center to Focus on Cardiac Safety and Innovation
6. New research center to focus on cardiac safety and innovation
7. Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety
8. Top Five International Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
9. Capnography Monitoring Significantly Improves Patient Safety during Procedural Sedation in the Emergency Department
10. FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDAs international posts, LASIK eye surgery, and FDA MedWatch safety alerts
11. Dramatic Settlement Sets National Model for H1N1 Hospital Safety Measures
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
XOLAIR Safety Study Continues to 2012 Despite Increased Rate of Occurrence of Heart Problems, Onder Law Firm Offers Free XOLAIR Case Review
(Date:4/30/2016)... ... 30, 2016 , ... “Aging well is a challenge for all of us, but there are things we can ... Kohli . “Research is showing more and more that there are simple, yet important steps ... as we age.” Top priorities Dr. Kohli’s recommends for her patients include;, , ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... In an ... mother and divorcee, shares her enthusiasm for Botox and lip injections, which she underwent ... famous youth oriented Coachella Valley Music and Arts Festival. The article explains that Ms. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily ... confront and deal with these stressors is to adopt a more healthful diet, but ... you. Risa Groux, a certified Holistic Nutritionist and the creator of the Newport Beach ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... in repaying their loans, more information about their loan terms and accounts, and ... student loan debt, including federal and private loans, has reached $1.3 trillion, with ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine ... announce one of their physicians has been invited to be a featured speaker at ... Practice Review conference on April 30, 2016. , Dr. R. Scott McPherson, a ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Global  urinalysis ... billion by 2022, according to a new report ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... efficiency and accuracy delivered by the new generation ... novel urinalysis instruments and consumables. For instance, the ...
(Date:4/27/2016)... -- At the Sachs CEO forum in ... 2 clinical study of its lead drug candidate, STR001, ... (CI) surgery. This large, placebo-controlled, double-blind, phase 2 study ... and France . STR001 is ... of surgery. "Despite advances in cochlear implant technology, a ...
(Date:4/26/2016)... , April 26, 2016 Hill-Rom Holdings, Inc. ... a management presentation at the Deutsche Bank 41 st ... 2:50 p.m. EDT. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas . ... hour after conclusion of the live event and accessible at ...
Breaking Medicine Technology: